{"id":121,"date":"2014-03-13T21:52:11","date_gmt":"2014-03-13T21:52:11","guid":{"rendered":"http:\/\/lupusgalicia.org\/Noticias\/?p=121"},"modified":"2014-03-14T09:30:03","modified_gmt":"2014-03-14T09:30:03","slug":"lupus-eritematoso-cutaneo-puede-avanzar-a-su-forma-sistemica","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=121","title":{"rendered":"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica"},"content":{"rendered":"\n\n\n
\n\n\n\n\n
\n

\u00abA los pacientes con LEC hay que controlarlos regularmente para detectar nuevos signos, s\u00edntomas o resultados de laboratorio, niveles elevados de antiDNA o proteinuria nuevos o en aumento\u00bb.<\/span><\/h1>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n

La mayor\u00eda de los pacientes con lupus eritematoso cut\u00e1neo (LEC) que desarrollan lupus eritematoso sist\u00e9mico (LES) no tienen s\u00edntomas sist\u00e9micos significativos, seg\u00fan revel\u00f3 un estudio longitudinal.<\/p>\n

\u00abExiste un riesgo de que la enfermedad avance a LES cuando los pacientes debutan con LEC solamente\u00bb, dijo la coautora del estudio, la doctora Victoria P. Werth, del Hospital de University of Pennsylvania, Filadelfia.<\/p>\n

\u00abDe hecho, existen criterios cl\u00ednicos suficientes para el LES, de modo que los pacientes con la enfermedad en la piel solamente pueden reunir esos criterios. En nuestra poblaci\u00f3n de pacientes con LEC, la mayor\u00eda no progresa a LES\u00bb, agreg\u00f3.<\/p>\n

El equipo de Werth caracteriz\u00f3 los tipos y la gravedad de los s\u00edntomas sist\u00e9micos en un estudio longitudinal sobre 77 pacientes con LEC. El 17 por ciento reun\u00eda los criterios de LES a los 8,03 a\u00f1os (en todos los casos, a los seis meses o m\u00e1s) desde el diagn\u00f3stico de LEC, seg\u00fan publica el equipo en JAMA Dermatology.<\/p>\n

En nueve de esos 13 pacientes apareci\u00f3 un nuevo s\u00edntomas y en cuatro pacientes surgieron dos s\u00edntomas m\u00e1s de LES. Esos criterios diagn\u00f3sticos adicionales fueron: compromiso hematol\u00f3gico (4 casos), artritis (3), erupci\u00f3n en forma de mariposa (3), complicaciones renales (2), fotosensibilidad (2), \u00falceras orales (dos) y erupci\u00f3n discoide (1).<\/p>\n

Ning\u00fan paciente tuvo complicaciones cardiopulmonares o neurol\u00f3gicas.<\/p>\n

Durante el seguimiento, cuatro pacientes con LES desarrollaron complicaciones musculoesquel\u00e9ticas y cuatro, enfermedad renal.<\/p>\n

Los 64 pacientes con LEC, sin evolucionar a LES, mostraron un leve compromiso sist\u00e9mico, mientras que el 62 por ciento de los que desarrollaron LES padeci\u00f3 el mismo problema y en el 38 por ciento con LES, la enfermedad sist\u00e9mica fue moderada o grave.<\/p>\n

Los t\u00edtulos basales de los anticuerpos antinucleares (ANA) fueron la \u00fanica caracter\u00edstica distintiva en los que la LEC evolucion\u00f3 a LES. Los pacientes con LEC \u00fanicamente a menudo ten\u00edan t\u00edtulos de ANA basales negativos.<\/p>\n

\u00abA los pacientes con LEC hay que controlarlos regularmente para detectar nuevos signos, s\u00edntomas o resultados de laboratorio, niveles elevados de dsDNA o proteinuria nuevos o en aumento\u00bb<\/strong>, indic\u00f3 Werth.<\/p>\n

\u00abAun as\u00ed, la progresi\u00f3n de la LEC a LES no indica autom\u00e1ticamente que el paciente desarrollar\u00e1 enfermedad moderada o grave. Muchos pacientes re\u00fanen los criterios de LES, pero sus resultados de los an\u00e1lisis de la piel y de laboratorio no exigen tratamiento\u00bb.<\/p>\n

\u00abLos pacientes deben saber que los que tienen la enfermedad cut\u00e1nea no evolucionar\u00e1n autom\u00e1ticamente a la enfermedad sist\u00e9mica moderada o grave\u00bb, insisti\u00f3 Werth.<\/p>\n

\u00abEse es un motivo de gran preocupaci\u00f3n para los pacientes y el mensaje es que hay que controlarlos, adem\u00e1s de comunicarles que, aunque re\u00fanan los criterios cl\u00ednicos de LES, existe un gran rango de gravedad de la enfermedad y que la mayor\u00eda desarrolla la forma leve.\u00bb<\/p>\n

El doctor Benjamin F. Chong, del Centro M\u00e9dico Southwestern de University of Texas, Dallas, y autor de un comentario sobre el estudio, dijo por e-mail: \u00abLa mayor\u00eda de los pacientes con LEC que desarrolla LES a menudo se queja de los problemas musculoesquel\u00e9ticos principalmente, sin complicaciones graves por el lupus. En la mayor\u00eda de los casos, es suficiente el manejo cl\u00ednico combinado con un reumat\u00f3logo\u00bb.<\/p>\n

Recomend\u00f3 realizar \u00abuna revisi\u00f3n sist\u00e9mica completa con an\u00e1lisis de laboratorio de todos los pacientes con LEC para detectar signos de avance de la enfermedad\u00bb.<\/p>\n

FUENTE: JAMA Dermatology, 2014 \u00a0Facilitada por la agencia Reuters. (Por Will Boggs)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

\u00abA los pacientes con LEC hay que controlarlos regularmente para detectar nuevos signos, s\u00edntomas o resultados de laboratorio, niveles elevados de antiDNA o proteinuria nuevos o en aumento\u00bb. La mayor\u00eda de los pacientes con lupus eritematoso cut\u00e1neo (LEC) que desarrollan lupus eritematoso sist\u00e9mico (LES) no tienen s\u00edntomas sist\u00e9micos significativos, seg\u00fan revel\u00f3 un estudio longitudinal. \u00abExiste […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[14,5],"tags":[44,16],"class_list":["post-121","post","type-post","status-publish","format-standard","hentry","category-estudios","category-lupus-internacional","tag-estudios","tag-tratamientos"],"yoast_head":"\r\nLupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=121\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"\u00abA los pacientes con LEC hay que controlarlos regularmente para detectar nuevos signos, s\u00edntomas o resultados de laboratorio, niveles elevados de antiDNA o proteinuria nuevos o en aumento\u00bb. La mayor\u00eda de los pacientes con lupus eritematoso cut\u00e1neo (LEC) que desarrollan lupus eritematoso sist\u00e9mico (LES) no tienen s\u00edntomas sist\u00e9micos significativos, seg\u00fan revel\u00f3 un estudio longitudinal. \u00abExiste […]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=121\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2014-03-13T21:52:11+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2014-03-14T09:30:03+00:00\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=121#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=121\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica\",\"datePublished\":\"2014-03-13T21:52:11+00:00\",\"dateModified\":\"2014-03-14T09:30:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=121\"},\"wordCount\":628,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"keywords\":[\"Estudios\",\"Tratamientos\"],\"articleSection\":[\"Estudios\",\"Lupus Internacional\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=121#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=121\",\"url\":\"https:\/\/lupusgalicia.org\/?p=121\",\"name\":\"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"datePublished\":\"2014-03-13T21:52:11+00:00\",\"dateModified\":\"2014-03-14T09:30:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=121#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=121\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=121#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=121","og_locale":"es_ES","og_type":"article","og_title":"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica - Asociaci\u00f3n Galega de Lupus","og_description":"\u00abA los pacientes con LEC hay que controlarlos regularmente para detectar nuevos signos, s\u00edntomas o resultados de laboratorio, niveles elevados de antiDNA o proteinuria nuevos o en aumento\u00bb. La mayor\u00eda de los pacientes con lupus eritematoso cut\u00e1neo (LEC) que desarrollan lupus eritematoso sist\u00e9mico (LES) no tienen s\u00edntomas sist\u00e9micos significativos, seg\u00fan revel\u00f3 un estudio longitudinal. \u00abExiste […]","og_url":"https:\/\/lupusgalicia.org\/?p=121","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2014-03-13T21:52:11+00:00","article_modified_time":"2014-03-14T09:30:03+00:00","author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=121#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=121"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica","datePublished":"2014-03-13T21:52:11+00:00","dateModified":"2014-03-14T09:30:03+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=121"},"wordCount":628,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"keywords":["Estudios","Tratamientos"],"articleSection":["Estudios","Lupus Internacional"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=121#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=121","url":"https:\/\/lupusgalicia.org\/?p=121","name":"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"datePublished":"2014-03-13T21:52:11+00:00","dateModified":"2014-03-14T09:30:03+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=121#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=121"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=121#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"Lupus eritematoso cut\u00e1neo puede avanzar a su forma sist\u00e9mica"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=121"}],"version-history":[{"count":2,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/121\/revisions"}],"predecessor-version":[{"id":127,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/121\/revisions\/127"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}